Analyzing...
Loading company...
No significant concerns identified
Nothing flagged for monitoring
“Operates in Pharmaceuticals — Formulations & API.”
₹4,118 Cr revenue.
COGS 59.1%, employees 17.4%.
“CDMO margins fell so sharply.”
“So '26, we'll have $25 million of revenue in the calendar year '26 coming in, and then similarly, in calendar year '27 as well, we'll have $25 million of revenue coming in the CDMO.”
“EBITDA margins.”
| KPI | Company | Sector Median |
|---|---|---|
| ROE | 10.1%▼ | 10.5% |
| ROCE | 9.5%▼ | 13.8% |
| Net Margin | 7.3%▼ | 8.7% |
| EBITDA Margin | 12.9%▼ | 16.0% |
| Debt To Equity | 0.00x▼ | 0.21x |
| (₹ Cr) | TTM | FY2025 |
|---|---|---|
| Revenue | ₹4,257 Cr +3.4% | ₹4,118 Cr |
| Other Income | ₹111 Cr +112.9% | ₹52 Cr |
| Total Income | ₹4,368 Cr +4.7% | ₹4,170 Cr |
| COGS | ₹2,492 Cr +2.4% | ₹2,433 Cr |
| ₹4,022 Cr +4.7% | ₹3,842 Cr | |
| Profit Before Tax | ₹336 Cr -2.7% | ₹345 Cr |
| Exceptional Items | (₹10 Cr) ↓ Decline | ₹17 Cr |
| ₹11 Cr +669.6% | ₹1 Cr | |
| Net Profit | ₹325 Cr -5.6% | ₹344 Cr |
| Profit (Owners) | ₹318 Cr -5.9% | ₹338 Cr |
| Minority Interest | ₹6 Cr +15.5% | ₹6 Cr |
| Other Comprehensive Income | (₹3 Cr) -162.7% | (₹1 Cr) |
| EPS | ₹20.21 | ₹21.49 |
| Diluted Shares | ₹16 Cr | ₹16 Cr |
No related party data available for this company.
This section will be populated when data becomes available.
Disclaimer · The Stock Filter is an information platform, not a SEBI-registered investment adviser. All data, scores, and narratives are generated from public filings and AI analysis — they do not constitute investment advice, recommendations, or endorsements. Always consult a qualified financial adviser before making investment decisions. Past performance does not guarantee future results.
Newspaper Advertisement- Information regarding 22nd AGM and Final & Special Dividend
Intimation of Schedule of the investor/analysts meets
Akums Drugs and Pharmaceuticals Limited has informed the Exchange about Schedule of meet
Receipt of Assessment Order(s) by certain subsidiaries from Income Tax Department
Transcript of Investors/Analysts Conference Call held for un-audited financial results of Q4 FY 2025-26 and audited financial results for FY 2025-26
Link of Audio Recording of Investor/Analysts Conference Call
Update on Disruption of Operations
Update on Disruption in Operations at some of the manufacturing sites at Haridwar
Intimation regarding Newspaper Publication
Akums Drugs and Pharmaceuticals Limited has informed the Exchange regarding a press release dated May 14, 2026, titled "Press Release".
Intimation of Disruption in Operations at some of the manufacturing sites at Haridwar
Akums Drugs and Pharmaceuticals Limited has informed the Exchange that Record date for the purpose of Dividend is 03-Jul-2026.
Changes in Senior Management Personnel
Appointment of Internal Auditors for the FY 2026-27
Re-appointment of Cost Auditors for the FY 2026-27
No dividend history available for this company.